Through PPARα-mediated regulation of inflammatory pathways and cellular metabolism, fenofibrate, PPARα agonist, exhibits combined neuroprotective and antidiabetic properties capable of ameliorating both Alzheimer’s disease pathology and type 2 diabetes complications [64]. The gene discussed is PPARA; the disease is early-onset autosomal dominant Alzheimer disease.